Alexander Mayweg

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Part of Bright Peak Therapeutics AG, Bright Peak Therapeutics, Inc. develops immunotherapies for the treatment of cancer and autoimmune diseases. The private company is based in San Diego, CA. The company was founded by Vijaya R. Pattabiraman, Jeffrey Bode. The CEO is Fredrik Wiklund.

Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland.

Part of Bright Peak Therapeutics AG, Bright Peak Therapeutics, Inc. develops immunotherapies for the treatment of cancer and autoimmune diseases. The private company is based in San Diego, CA. The company was founded by Vijaya R. Pattabiraman, Jeffrey Bode. The CEO is Fredrik Wiklund.

T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany.

Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom.

Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom.

Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom.

Cimeio Therapeutics AG is an applied gene editing and immunotherapy company based in Basel, Switzerland. Cimeio is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip) that have the potential to transform hematopoietic stem cell transplant. The Swiss company's technology platform is based on the design and expression of modified variants of naturally occurring cell surface proteins in hscs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. Cimeio is the leader of the field of epitope editing and is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip), novel immunotherapies which have the potential to transform treatment of hematologic diseases. The company develops state-of-the-art immunotherapies, along with paired, modified variants of naturally occurring cell surface proteins in hscs. These immunotherapies have significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with hematologic malignancies, autoimmune disorders, and genetic diseases. The company was founded by Lukas Jeker and the CEO is Thomas Fuchs.

Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland.

Part of Bright Peak Therapeutics AG, Bright Peak Therapeutics, Inc. develops immunotherapies for the treatment of cancer and autoimmune diseases. The private company is based in San Diego, CA. The company was founded by Vijaya R. Pattabiraman, Jeffrey Bode. The CEO is Fredrik Wiklund.

Part of Bright Peak Therapeutics AG, Bright Peak Therapeutics, Inc. develops immunotherapies for the treatment of cancer and autoimmune diseases. The private company is based in San Diego, CA. The company was founded by Vijaya R. Pattabiraman, Jeffrey Bode. The CEO is Fredrik Wiklund.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Cimeio Therapeutics AG is an applied gene editing and immunotherapy company based in Basel, Switzerland. Cimeio is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip) that have the potential to transform hematopoietic stem cell transplant. The Swiss company's technology platform is based on the design and expression of modified variants of naturally occurring cell surface proteins in hscs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. Cimeio is the leader of the field of epitope editing and is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip), novel immunotherapies which have the potential to transform treatment of hematologic diseases. The company develops state-of-the-art immunotherapies, along with paired, modified variants of naturally occurring cell surface proteins in hscs. These immunotherapies have significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with hematologic malignancies, autoimmune disorders, and genetic diseases. The company was founded by Lukas Jeker and the CEO is Thomas Fuchs.

T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany.

Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom.

Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom.

Part of Bright Peak Therapeutics AG, Bright Peak Therapeutics, Inc. develops immunotherapies for the treatment of cancer and autoimmune diseases. The private company is based in San Diego, CA. The company was founded by Vijaya R. Pattabiraman, Jeffrey Bode. The CEO is Fredrik Wiklund.

Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland.

Part of Bright Peak Therapeutics AG, Bright Peak Therapeutics, Inc. develops immunotherapies for the treatment of cancer and autoimmune diseases. The private company is based in San Diego, CA. The company was founded by Vijaya R. Pattabiraman, Jeffrey Bode. The CEO is Fredrik Wiklund.

Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland.

Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland.

Part of Bright Peak Therapeutics AG, Bright Peak Therapeutics, Inc. develops immunotherapies for the treatment of cancer and autoimmune diseases. The private company is based in San Diego, CA. The company was founded by Vijaya R. Pattabiraman, Jeffrey Bode. The CEO is Fredrik Wiklund.

Part of Bright Peak Therapeutics AG, Bright Peak Therapeutics, Inc. develops immunotherapies for the treatment of cancer and autoimmune diseases. The private company is based in San Diego, CA. The company was founded by Vijaya R. Pattabiraman, Jeffrey Bode. The CEO is Fredrik Wiklund.

Cimeio Therapeutics AG is an applied gene editing and immunotherapy company based in Basel, Switzerland. Cimeio is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip) that have the potential to transform hematopoietic stem cell transplant. The Swiss company's technology platform is based on the design and expression of modified variants of naturally occurring cell surface proteins in hscs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. Cimeio is the leader of the field of epitope editing and is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip), novel immunotherapies which have the potential to transform treatment of hematologic diseases. The company develops state-of-the-art immunotherapies, along with paired, modified variants of naturally occurring cell surface proteins in hscs. These immunotherapies have significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with hematologic malignancies, autoimmune disorders, and genetic diseases. The company was founded by Lukas Jeker and the CEO is Thomas Fuchs.

T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany.

T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany.

Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver.

Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom.

T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany.

Monte Rosa Therapeutics AG develops, manufactures and distributes cancer drugs that modulate protein degradation pathways. The company was founded in 2018 and is headquartered in Basel, Switzerland.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom.

Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom.

T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany.

Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver.

Cimeio Therapeutics AG is an applied gene editing and immunotherapy company based in Basel, Switzerland. Cimeio is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip) that have the potential to transform hematopoietic stem cell transplant. The Swiss company's technology platform is based on the design and expression of modified variants of naturally occurring cell surface proteins in hscs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. Cimeio is the leader of the field of epitope editing and is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip), novel immunotherapies which have the potential to transform treatment of hematologic diseases. The company develops state-of-the-art immunotherapies, along with paired, modified variants of naturally occurring cell surface proteins in hscs. These immunotherapies have significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with hematologic malignancies, autoimmune disorders, and genetic diseases. The company was founded by Lukas Jeker and the CEO is Thomas Fuchs.

Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland.